Close this search box.

Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Collaborating Groups


Participating Centres

Accrual Target


Current Accrual

Trial Chairperson

Prof Andrew Scott - Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC
A/Prof Eng-Siew Koh - Liverpool Hospital, NSW

Trial Contact

Clinical Trial Registration

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing